Natural History of Primary IgA Nephropathy
Section snippets
Definition of IgAN
The definition of IgAN is pathologic and still needs a renal biopsy which should be examined at least by light microscopy (LM) and by immunofluorescence microscopy. The immunofluorescence microscopy technique, necessary for identification of mesangial IgA deposits, appeared in the late 1960s, explaining why IgAN was not identified earlier. The agreed on definition is the presence of at least 1+ (on a semiquantitative scale: 0, trace, 1+, 2+, and 3+) IgA deposits in the mesangial area (also
Classification of IgAN
The spectrum of IgA nephropathies is dominated by idiopathic or primary IgAN, previously also called Berger’s disease. In our own center, an initial cohort diagnosed from 1975 to 19873 consisted of 356 patients, with 282 cases (79%) of primary IgAN, 41 cases (11.5%) secondary to Schönlein-Henoch purpura, and 33 cases (9%) secondary to cirrhosis. Similar histologic appearances may be seen in systemic lupus erythematosus, International Society of Nephrology/Renal Pathology Society (ISN/RPS) class
Epidemiology of Primary IgAN
IgAN is diagnosed worldwide, and remains the most predominant primary glomerulonephritis. It is frequent in Caucasian and Asian populations, contrasting with its apparent rarity in African populations, especially in African Americans.7
Its incidence has been estimated in France to be between 26 and 30 new cases per million population (pmp) in 2 different regions: Britanny8 and Rhône-Alpes.9 In Japanese children,10 the incidence was calculated at 45 pmp (with both sporadically identified cases
Clinical Onset of the Disease
Depending on the renal biopsy policy, extended versus restricted, the proportion of patients diagnosed at the time of an acute episode compared with those who are asymptomatic (urinary screening detection) will vary greatly, ranging from 30%3 to 80%14 both in children and adults.
The typical acute presentation is macroscopic hematuria at time of a mucosal infectious event (upper respiratory tract infection, bronchitis, or even urinary tract infection). Episodes last for 2 or 3 days, and usually
Progression of IgAN
The natural history of primary IgAN is progression both clinically and pathologically.
Clinical progression is exemplified by our prospective cohort, with collection of 332 new cases over a 10-year period from 1990 to 1999 (Table 2). With time, there is clearly a progression of the number of patients with hypertension (HT), with chronic renal failure (CRF) (defined as stage 3 or 4 CKD [GFR <60 mL/min/1.73 m2]), or reaching ESRD. The overall prevalence of CRF in other series varied from 9% to
Predictive Risk Factors of Progression in IgAN
A major step to be performed at the time of diagnosis in each individual case is to establish as accurately as possible the long-term prognosis with an appropriate management plan and follow-up procedure.
There is now a consensus about the 3 major risk factors predictive of progression toward CKD and ESRD.
The occurrence of arterial HT is the most important. By Cox regression analyses (univariate, then multivariate), HT occurring at any stage of the disease is an independent and strong risk
Conclusions
The natural history of IgAN is dominated by clinical and pathologic progression. The rate of progression to CKD and ESRD is highly variable among patients, from very fast to very slow (ie, from a few years to >50 years). It is possible to predict long-term prognosis at the time of initial diagnosis with 3 independent risk factors: occurrence of arterial HT, amount of proteinuria, and severity of some renal lesions. The natural history of the disease should be observed carefully and every effort
References (37)
- et al.
Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses
Am J Kidney Dis
(1991) Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors
Am J Kidney Dis
(2000)- et al.
Epidemiologic data of primary glomerular diseases in western France
Kidney Int
(2004) - et al.
Natural history and risk factors for immunoglobulin A nephropathy in JapanResearch Group on Progressive Renal Diseases
Am J Kidney Dis
(1997) - et al.
A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study
Am J Kidney Dis
(2007) Histologic subclassification of IgA nephropathy: a clinicopathological study of 244 cases
Am J Kidney Dis
(1997)- et al.
Predicting progression in IgA nephropathy
Am J Kidney Dis
(2001) Predicting prognosis in IgA nephropathy: editorial
Am J Kidney Dis
(2001)- et al.
Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis
Am J Kidney Dis
(2001) - et al.
The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy
Kidney Int
(2005)
CC-chemokine receptor five gene polymorphism in primary IgA nephropathy: the 32 bp deletion allele is associated with late progression to end-stage renal failure with dialysis
Kidney Int
Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
Am J Kidney Dis
Intercapillary deposits of IgA-IgG
J Urol Nephrol
IgA glomerular deposits in renal disease
Transplant Proc
IgA nephropathy
N Engl J Med
IgA nephropathy
J Am Soc Nephrol
A retrospective analysis of the natural history of primary IgA nephropathy worldwide
Am J Med
et les néphrologues de la regionIncidence annuelle des glomérulonéphrites en 1987-1988 dans la région Rhône-Alpes élargie
Presse Med
Cited by (140)
Systematic Review of the Link Between Oxford MEST-C Classification and Complement Activation in IgA Nephropathy
2024, Kidney International ReportsClinical Presentation, Pathological Spectrum, and Outcomes of Alcoholic Cirrhosis-Related Immunoglobulin A Nephropathy
2024, Kidney International ReportsClinicopathological Characteristics of Adult IgA Nephropathy in the United States
2023, Kidney International ReportsTargeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
2023, Kidney International ReportsParticulate matter of air pollution may increase risk of kidney failure in IgA nephropathy
2022, Kidney InternationalHigh value of early secretory antigenic target-6 and culture filtrate protein-10 in diagnosis of IgA nephropathy with renal tuberculosis: a retrospective study
2022, American Journal of the Medical Sciences